Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)
Johnson & Johnson has submitted two supplemental Biologics License Applications (sBLAs) to the FDA for TREMFYA® (guselkumab), seeking approval for treating children aged 6+ with moderate-to-severe plaque psoriasis and children aged 5+ with active juvenile psoriatic arthritis. The submissions are based on data from the Phase 3 PROTOSTAR study, along with pharmacokinetic data from adult studies VOYAGE 1 and 2 for psoriasis, and DISCOVER 1 and 2 for psoriatic arthritis. TREMFYA® is the first approved monoclonal antibody that selectively targets the p19 subunit of IL-23.
Johnson & Johnson ha presentato due domande supplementari di licenza biologica (sBLA) alla FDA per TREMFYA® (guselkumab), cercando l'approvazione per il trattamento di bambini di età superiore ai 6 anni con psoriasi a placche da moderata a grave e di bambini di età superiore ai 5 anni con artrite psoriatica giovanile attiva. Le presentazioni si basano su dati dello studio di fase 3 PROTOSTAR, insieme ai dati farmacocinetici provenienti dagli studi VOYAGE 1 e 2 per la psoriasi, e DISCOVER 1 e 2 per l'artrite psoriatica. TREMFYA® è il primo anticorpo monoclonale approvato che colpisce selettivamente la sottounità p19 dell'IL-23.
Johnson & Johnson ha presentado dos solicitudes suplementarias de licencia biológica (sBLA) a la FDA para TREMFYA® (guselkumab), buscando la aprobación para tratar a niños de 6 años o más con psoriasis en placas de moderada a severa y a niños de 5 años o más con artritis psoriásica juvenil activa. Las presentaciones se basan en datos del estudio de fase 3 PROTOSTAR, junto con datos farmacocinéticos de estudios en adultos VOYAGE 1 y 2 para psoriasis y DISCOVER 1 y 2 para artritis psoriásica. TREMFYA® es el primer anticuerpo monoclonal aprobado que se dirige selectivamente a la subunidad p19 de IL-23.
존슨 & 존슨은 FDA에 TREMFYA® (구셀쿠맙)에 대한 두 개의 보충 생물학적 라이센스 신청서(sBLA)를 제출하여, 중증 플라크 건선으로 고통받는 6세 이상의 어린이와 활동성 소아 건선 관절염으로 고통받는 5세 이상의 어린이를 치료할 수 있도록 승인을 요청했습니다. 이 제출서는 3상 PROTOSTAR 연구의 데이터와 성인 연구인 VOYAGE 1 및 2(건선) 및 DISCOVER 1 및 2(건선 관절염)의 약리학적 데이터에 기반하고 있습니다. TREMFYA®는 IL-23의 p19 소단위를 선택적으로 표적하는 최초의 승인된 단일클론 항체입니다.
Johnson & Johnson a soumis deux demandes de licence biologique supplémentaire (sBLA) à la FDA pour TREMFYA® (guselkumab), cherchant à obtenir l'approbation pour le traitement des enfants âgés de 6 ans et plus atteints de psoriasis en plaques modéré à sévère et des enfants âgés de 5 ans et plus atteints d'arthrite psoriasique juvénile active. Les soumissions sont basées sur des données de l'étude de phase 3 PROTOSTAR, ainsi que sur des données pharmacocinétiques provenant des études VOYAGE 1 et 2 pour le psoriasis, et DISCOVER 1 et 2 pour l'arthrite psoriasique. TREMFYA® est le premier anticorps monoclonal approuvé ciblant sélectivement la sous-unité p19 de l'IL-23.
Johnson & Johnson hat zwei ergänzende Anträge auf biologische Lizenz (sBLA) bei der FDA für TREMFYA® (guselkumab) eingereicht, um die Genehmigung zur Behandlung von Kindern ab 6 Jahren mit moderater bis schwerer Plaque-Psoriasis und von Kindern ab 5 Jahren mit aktiver juveniler psoriatischer Arthritis zu beantragen. Die Anträge basieren auf Daten aus der Phase-3-Studie PROTOSTAR sowie auf pharmakokinetischen Daten aus den Erwachsenestudien VOYAGE 1 und 2 zur Psoriasis sowie DISCOVER 1 und 2 zur psoriatischen Arthritis. TREMFYA® ist der erste genehmigte monoklonale Antikörper, der selektiv die p19-Untereinheit von IL-23 angreift.
- Potential market expansion into pediatric indications
- First-in-class selective IL-23 inhibitor seeking pediatric approval
- Leveraging existing clinical data to support pediatric applications
- Current lack of pediatric approval limits market reach
- Reliance on extrapolated adult data for pediatric applications
Insights
The sBLA submissions for TREMFYA® represent a significant expansion into pediatric indications for J&J's immunology portfolio. The drug's unique mechanism targeting IL-23's p19 subunit could offer advantages over existing pediatric treatments. The PROTOSTAR study data, combined with adult trial extrapolation, provides a robust scientific foundation for these applications.
Pediatric approvals could substantially expand TREMFYA's market reach. Currently approved competitors in pediatric psoriasis include Cosentyx, Enbrel and Humira, making this a competitive but lucrative space. The dual submission strategy for both plaque psoriasis and juvenile psoriatic arthritis could maximize commercial potential if approved. Annual TREMFYA sales could see meaningful growth from these new indications, considering the drug already generates over
This regulatory filing targets an underserved but valuable market segment. The pediatric immunology market presents a significant growth opportunity, with increasing diagnosis rates and treatment options. Success in these indications would strengthen J&J's competitive position against rivals like AbbVie and Novartis in the pediatric space.
The timing is strategic, as several competing biologics face biosimilar competition, potentially creating a market opportunity for TREMFYA. A positive FDA decision could drive meaningful revenue growth, particularly given the long-term nature of these chronic conditions and the potential for early patient capture leading to continued use into adulthood.
Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis
The PsO submission is based on data from the Phase 3 PROTOSTAR study in pediatric patients with moderate to severe plaque PsO and bridging pharmacokinetic (PK) data from the Phase 3 VOYAGE 1 and 2 studies in adult patients with moderate to severe plaque PsO. The jPsA submission is based on PK extrapolation analyses from adult PsA studies (DISCOVER 1 and 2) and TREMFYA efficacy and safety data from the PROTOSTAR study.b
"This milestone underscores our commitment to transform the standard of care for patients of all ages and builds on our expertise and legacy in IL-23 and immune-mediated diseases," said Liza O'Dowd, M.D., Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson Innovative Medicine. "There is a critical gap in the treatment of children and adolescents with these skin and joint conditions, where debilitating symptoms can present challenges related to physical appearance and ability to function. At Johnson & Johnson, we are working to address this gap by investigating the efficacy and well-characterized safety profile of TREMFYA for pediatric patients."
TREMFYA® is the first approved monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is an important driver of immune-mediated diseases such as plaque PsO and PsA.
Editor's Notes:
a. | TREMFYA® is not currently approved to treat moderate to severe pediatric plaque psoriasis or active juvenile psoriatic arthritis (jPsA). |
b. | Data extrapolation is the process of estimating future trends or effects based on previous observations. With limited pediatric patients available for clinical trial inclusion, researchers can extrapolate data from adult patient trials to determine the potential efficacy and tolerability of a treatment for the pediatric population. |
ABOUT PEDIATRIC PLAQUE PSORIASIS
Plaque psoriasis (PsO) is an immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.1 Almost one-third of PsO cases begin in childhood, with roughly 20,000 children under 10 diagnosed with psoriasis each year.1 Having visible skin disease can be highly stressful for children and adolescents and can have a long-term impact on those affected.2
ABOUT JUVENILE PSORIATIC ARTHRITIS
Juvenile psoriatic arthritis (jPsA) is a form of juvenile idiopathic arthritis (JIA) characterized by chronic joint inflammation, swelling and psoriasis. Juvenile PsA is relatively rare, accounting for approximately
ABOUT THE PHASE 3 PROTOSTAR STUDY (NCT03451851)
PROTOSTAR is a Phase 3, multicenter, randomized, placebo- and active comparator-controlled study evaluating the efficacy, safety, and pharmacokinetics of subcutaneously administered TREMFYA® for the treatment of chronic plaque psoriasis in pediatric patients six years of age and older. Co-primary endpoints of the study were Investigator's Global Assessment (IGA) 0/1 and PASI 75 at Week 16.4
ABOUT THE PHASE 3 VOYAGE STUDIES (NCT02207231 and NCT02207244)
VOYAGE 1 and 2 were Phase 3 randomized, double-blind, placebo- and active comparator-controlled studies designed to evaluate the efficacy and safety of TREMFYA® compared with placebo and adalimumab in adults with moderate to severe plaque PsO. The co-primary endpoints of the studies were the proportions of patients receiving TREMFYA® versus patients receiving placebo achieving Investigator's Global Assessment (IGA) 0/1 (clear/almost clear skin) and PASI 90 at week 16.5,6
ABOUT THE PHASE 3 DISCOVER STUDIES (NCT03162796 and NCT03158285)
DISCOVER-1 was a Phase 3, multicenter, randomized, double-blind study evaluating the efficacy and safety of TREMFYA® administered by subcutaneous injection in participants with active PsA, including those previously treated with one to two tumor necrosis factor inhibitors (TNFi). The primary endpoint was response of ACR20 at week 24.7 DISCOVER-2 was a Phase 3, multicenter, randomized, double-blind study evaluating the efficacy and safety of TREMFYA® administered by subcutaneous injection in biologic-naïve patients with active PsA. The primary endpoint was response of ACR20 at week 24.8
ABOUT TREMFYA® (guselkumab)
Developed by Johnson & Johnson, TREMFYA® is the first approved fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cell that produce IL-23). Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.
TREMFYA® is a prescription medicine approved in the
- adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
- adults with active psoriatic arthritis.
- adults with moderately to severely active ulcerative colitis.9
TREMFYA® is approved
Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA®. For more information, visit: www.tremfya.com.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA® (guselkumab)?
TREMFYA® is a prescription medicine that may cause serious side effects, including:
- Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
ο fainting, dizziness, feeling lightheaded ο swelling of your face, eyelids, lips, mouth,
|
ο trouble breathing or throat tightness ο chest tightness ο skin rash, hives ο itching
|
- Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
ο fever, sweats, or chills ο muscle aches ο weight loss ο cough ο warm, red, or painful skin or sores on your body different from
|
ο diarrhea or stomach pain ο shortness of breath ο blood in your phlegm (mucus) ο burning when you urinate or
|
Do not take TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.
Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:
- have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA®?"
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®.
- are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA®, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA®. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing MotherToBaby@health.ucsd.edu. The purpose of this registry is to collect information about the safety of TREMFYA® during pregnancy. - are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA®?
TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?"
The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, and bronchitis.
These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.
Use TREMFYA® exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA® and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA® is available in a 100 mg/mL prefilled syringe and One-Press patient-controlled injector for subcutaneous injection, a 200 mg/2 mL prefilled syringe and prefilled pen (TREMFYA® PEN) for subcutaneous injection, and a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at https://www.innovativemedicine.jnj.com/. Follow us at @JNJInnovMed. Janssen Research & Development, LLC and Janssen Biotech, Inc. are Johnson & Johnson companies.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding TREMFYA®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
1 National Psoriasis Foundation. About psoriasis. Available at: https://www.psoriasis.org/children-with-psoriasis/. Accessed October 2024.
2 Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015 Oct;17(5):373-84. doi: 10.1007/s40272-015-0137-1.
3 Brunello, Francesco et al. New Insights on Juvenile Psoriatic Arthritis. Frontiers in pediatrics. 2022. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9199423/#:~:text=Juvenile%20psoriatic%20arthritis%20(JPsA)%20is,Idiopathic%20Arthritis%20(JIA)%20population. Accessed October 2024.
4 ClinicalTrials.gov.A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PROTOSTAR). Identifier: NCT03451851. Available at: https://clinicaltrials.gov/study/NCT03451851
5 Clinicaltrials.gov. A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1). Identifier NCT02207231. https://www.clinicaltrials.gov/ct2/show/NCT02207231. Accessed October 2024.
6 Clinicaltrials.gov. A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2). Identifier NCT02207244. https://www.clinicaltrials.gov/ct2/show/NCT02207244. Accessed October 2024.
7 ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-Tumor Necrosis Factor (TNF) Alpha Agent(s) (DISCOVER 1). Identifier: NCT03162796. Available at: https://clinicaltrials.gov/ct2/show/NCT03162796. Accessed October 2024.
8 ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis. Identifier: NCT03158285. Available at: https://clinicaltrials.gov/ct2/show/NCT03158285. Accessed October 2024.
9 TREMFYA® Prescribing Information. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed October 2024.
Media contact: | Investor contact: |
Craig Stoltz | Lauren Johnson |
+1 215-779-9396 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-seeks-us-fda-approval-for-first-pediatric-indications-for-tremfya-guselkumab-302317847.html
SOURCE Johnson & Johnson
FAQ
What new indications is Johnson & Johnson (JNJ) seeking for TREMFYA?
What clinical studies support TREMFYA's pediatric applications for JNJ?
How does TREMFYA work in JNJ's treatment approach?
